Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.08
MASI's Cash to Debt is ranked lower than
51% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 1.18 vs. MASI: 1.08 )
Ranked among companies with meaningful Cash to Debt only.
MASI' s 10-Year Cash to Debt Range
Min: 0.49   Max: N/A
Current: 1.08

Equity to Asset 0.56
MASI's Equity to Asset is ranked higher than
55% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 0.52 vs. MASI: 0.56 )
Ranked among companies with meaningful Equity to Asset only.
MASI' s 10-Year Equity to Asset Range
Min: -1.01   Max: 0.81
Current: 0.56

-1.01
0.81
F-Score: 5
Z-Score: 7.04
M-Score: -2.92
WACC vs ROIC
8.94%
25.39%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 16.74
MASI's Operating margin (%) is ranked higher than
88% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: -10.56 vs. MASI: 16.74 )
Ranked among companies with meaningful Operating margin (%) only.
MASI' s 10-Year Operating margin (%) Range
Min: -13.85   Max: 137.71
Current: 16.74

-13.85
137.71
Net-margin (%) 11.71
MASI's Net-margin (%) is ranked higher than
87% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: -12.96 vs. MASI: 11.71 )
Ranked among companies with meaningful Net-margin (%) only.
MASI' s 10-Year Net-margin (%) Range
Min: -14.75   Max: 81.05
Current: 11.71

-14.75
81.05
ROE (%) 22.20
MASI's ROE (%) is ranked higher than
95% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: -14.48 vs. MASI: 22.20 )
Ranked among companies with meaningful ROE (%) only.
MASI' s 10-Year ROE (%) Range
Min: 17.28   Max: 40.82
Current: 22.2

17.28
40.82
ROA (%) 13.39
MASI's ROA (%) is ranked higher than
94% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: -7.12 vs. MASI: 13.39 )
Ranked among companies with meaningful ROA (%) only.
MASI' s 10-Year ROA (%) Range
Min: -19.03   Max: 140.05
Current: 13.39

-19.03
140.05
ROC (Joel Greenblatt) (%) 67.83
MASI's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: -26.51 vs. MASI: 67.83 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MASI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 51.15   Max: 1358.08
Current: 67.83

51.15
1358.08
Revenue Growth (3Y)(%) 13.60
MASI's Revenue Growth (3Y)(%) is ranked higher than
90% of the 376 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MASI: 13.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MASI' s 10-Year Revenue Growth (3Y)(%) Range
Min: -19.3   Max: 30.3
Current: 13.6

-19.3
30.3
EBITDA Growth (3Y)(%) 10.70
MASI's EBITDA Growth (3Y)(%) is ranked higher than
87% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MASI: 10.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MASI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 259.6
Current: 10.7

0
259.6
EPS Growth (3Y)(%) 7.40
MASI's EPS Growth (3Y)(%) is ranked higher than
86% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MASI: 7.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MASI' s 10-Year EPS Growth (3Y)(%) Range
Min: -33.8   Max: 45.9
Current: 7.4

-33.8
45.9
» MASI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

MASI Guru Trades in Q2 2014

Jim Simons 262,235 sh (New)
Joel Greenblatt 73,956 sh (+91.22%)
Paul Tudor Jones 37,000 sh (+51.02%)
Mario Gabelli 122,000 sh (+35.56%)
Jeremy Grantham 88,800 sh (+6.47%)
Pioneer Investments Sold Out
Ron Baron 758,386 sh (-44.50%)
» More
Q3 2014

MASI Guru Trades in Q3 2014

Jim Simons 336,200 sh (+28.21%)
Paul Tudor Jones 41,800 sh (+12.97%)
Mario Gabelli 125,000 sh (+2.46%)
Jeremy Grantham 75,535 sh (-14.94%)
Joel Greenblatt 55,059 sh (-25.55%)
Ron Baron 16,760 sh (-97.79%)
» More
Q4 2014

MASI Guru Trades in Q4 2014

Mario Gabelli 134,000 sh (+7.20%)
Joel Greenblatt Sold Out
Ron Baron Sold Out
Jeremy Grantham 54,600 sh (-27.72%)
Paul Tudor Jones 22,872 sh (-45.28%)
Jim Simons 100,100 sh (-70.23%)
» More
Q1 2015

MASI Guru Trades in Q1 2015

Joel Greenblatt 42,408 sh (New)
Chuck Royce 441,000 sh (New)
Jim Simons 142,700 sh (+42.56%)
Mario Gabelli 134,000 sh (unchged)
Paul Tudor Jones Sold Out
Jeremy Grantham 52,900 sh (-3.11%)
» More
» Details

Insider Trades

Latest Guru Trades with MASI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 27.60
MASI's P/E(ttm) is ranked higher than
77% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MASI: 27.60 )
Ranked among companies with meaningful P/E(ttm) only.
MASI' s 10-Year P/E(ttm) Range
Min: 16.96   Max: 91.05
Current: 27.6

16.96
91.05
Forward P/E 23.53
MASI's Forward P/E is ranked higher than
73% of the 378 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MASI: 23.53 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 27.60
MASI's PE(NRI) is ranked higher than
81% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MASI: 27.60 )
Ranked among companies with meaningful PE(NRI) only.
MASI' s 10-Year PE(NRI) Range
Min: 17.04   Max: 66.16
Current: 27.6

17.04
66.16
P/B 5.80
MASI's P/B is ranked lower than
78% of the 368 Companies
in the Global Medical Devices industry.

( Industry Median: 3.30 vs. MASI: 5.80 )
Ranked among companies with meaningful P/B only.
MASI' s 10-Year P/B Range
Min: 3.54   Max: 15.2
Current: 5.8

3.54
15.2
P/S 3.25
MASI's P/S is ranked lower than
57% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MASI: 3.25 )
Ranked among companies with meaningful P/S only.
MASI' s 10-Year P/S Range
Min: 1.77   Max: 9.79
Current: 3.25

1.77
9.79
POCF 21.44
MASI's POCF is ranked higher than
79% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MASI: 21.44 )
Ranked among companies with meaningful POCF only.
MASI' s 10-Year POCF Range
Min: 2.16   Max: 51.16
Current: 21.44

2.16
51.16
EV-to-EBIT 18.50
MASI's EV-to-EBIT is ranked higher than
85% of the 382 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MASI: 18.50 )
Ranked among companies with meaningful EV-to-EBIT only.
MASI' s 10-Year EV-to-EBIT Range
Min: 6.3   Max: 117.2
Current: 18.5

6.3
117.2
PEG 7.08
MASI's PEG is ranked higher than
90% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MASI: 7.08 )
Ranked among companies with meaningful PEG only.
MASI' s 10-Year PEG Range
Min: 4.3   Max: 577.5
Current: 7.08

4.3
577.5
Shiller P/E 30.70
MASI's Shiller P/E is ranked higher than
81% of the 372 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MASI: 30.70 )
Ranked among companies with meaningful Shiller P/E only.
MASI' s 10-Year Shiller P/E Range
Min: 14.04   Max: 31.15
Current: 30.7

14.04
31.15
Current Ratio 2.69
MASI's Current Ratio is ranked higher than
61% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 2.04 vs. MASI: 2.69 )
Ranked among companies with meaningful Current Ratio only.
MASI' s 10-Year Current Ratio Range
Min: 1.25   Max: 4.87
Current: 2.69

1.25
4.87
Quick Ratio 2.10
MASI's Quick Ratio is ranked higher than
62% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 1.53 vs. MASI: 2.10 )
Ranked among companies with meaningful Quick Ratio only.
MASI' s 10-Year Quick Ratio Range
Min: 0.99   Max: 4.34
Current: 2.1

0.99
4.34
Days Inventory 115.45
MASI's Days Inventory is ranked higher than
70% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 198.08 vs. MASI: 115.45 )
Ranked among companies with meaningful Days Inventory only.
MASI' s 10-Year Days Inventory Range
Min: 55.77   Max: 117.9
Current: 115.45

55.77
117.9
Days Sales Outstanding 41.32
MASI's Days Sales Outstanding is ranked higher than
90% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 96.55 vs. MASI: 41.32 )
Ranked among companies with meaningful Days Sales Outstanding only.
MASI' s 10-Year Days Sales Outstanding Range
Min: 36.51   Max: 52.39
Current: 41.32

36.51
52.39

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 6.80
MASI's Price/Tangible Book is ranked lower than
64% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 5.30 vs. MASI: 6.80 )
Ranked among companies with meaningful Price/Tangible Book only.
MASI' s 10-Year Price/Tangible Book Range
Min: 4.11   Max: 15.3
Current: 6.8

4.11
15.3
Price/DCF (Projected) 2.20
MASI's Price/DCF (Projected) is ranked higher than
77% of the 375 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MASI: 2.20 )
Ranked among companies with meaningful Price/DCF (Projected) only.
MASI' s 10-Year Price/DCF (Projected) Range
Min: 1.22   Max: 2.5
Current: 2.2

1.22
2.5
Price/Median PS Value 1.00
MASI's Price/Median PS Value is ranked higher than
68% of the 383 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MASI: 1.00 )
Ranked among companies with meaningful Price/Median PS Value only.
MASI' s 10-Year Price/Median PS Value Range
Min: 0.65   Max: 2.82
Current: 1

0.65
2.82
Price/Graham Number 2.80
MASI's Price/Graham Number is ranked higher than
73% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MASI: 2.80 )
Ranked among companies with meaningful Price/Graham Number only.
MASI' s 10-Year Price/Graham Number Range
Min: 1.76   Max: 5.96
Current: 2.8

1.76
5.96
Earnings Yield (Greenblatt) 5.40
MASI's Earnings Yield (Greenblatt) is ranked higher than
85% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: -2.60 vs. MASI: 5.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
MASI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.9   Max: 15.8
Current: 5.4

0.9
15.8
Forward Rate of Return (Yacktman) 3.86
MASI's Forward Rate of Return (Yacktman) is ranked higher than
87% of the 371 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MASI: 3.86 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) only.
MASI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -2.6   Max: 14.1
Current: 3.86

-2.6
14.1

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:3M4.Germany,
Masimo Corp was incorporated in California in May 1989 and reincorporated in Delaware in May 1996. The Company is a medical technology company that develops, manufactures, and markets a variety of noninvasive monitoring technologies. Its core business is measure through motion and low perfusion arterial blood oxygen saturation and pulse rate monitoring, known as Masimo SET pulse oximetry, but our product offerings have expanded significantly over the years to also include noninvasive blood constituent, brain and breath monitoring, including rainbow Pulse CO-Oximetry, brain function electroencephalogram (EEG) monitoring, respiration rate, capnography and anesthetic agent monitoring. In addition, they have developed the Root patient monitoring and connectivity platform and Patient SafetyNet remote patient surveillance monitoring system. They provide their products directly and through distributors and OEM partners to hospitals, emergency medical service (EMS) providers, physician offices, veterinarians, long term care facilities and consumers. The Company sell their products to end-users through its direct sales force and certain distributors, as well as its OEM partners, for incorporation into their products. They also offer a patient surveillance or remote monitoring and clinician notification solution called Patient SafetyNet, which includes Masimo SET or rainbow SET platform measurements at the patient's bedside along with a central assignment station and wired or wireless server. In October 2012, they received both FDA clearance for uSpO2, a universal "Board-in-Cable" pulse oximetry solution, enabling easier and faster integration for OEM partners due to the ability to integrate Masimo SET through software only. The Company acquired Spire Semiconductor, LLC, a maker of advanced light emitting diode and other advanced component-level technologies. Masimo Semiconductor, Inc. (Masimo Semiconductor), its wholly owned subsidiary, operates this business and specializes in wafer epitaxy, foundry services, and device fabrication for biomedical, telecommunications, consumer products and other markets. The Company offer Masimo SET and rainbow SET through its OEMs for integration in their products and through its own end-user products, including the Root, Radical-7, Rad-87, Rad-57, Pronto-7, Pronto, Rad-8, Rad-5 and Rad-5v. The Company has 674 issued and pending patents worldwide. They have licensed from Cercacor Laboratories, Inc. (Cercacor), the right to OEM selected rainbow technology and to incorporate selected rainbow technology into their products intended to be used by professional caregivers, including, but not limited to, hospital caregivers and alternate care facility caregivers. The Company is subject to U.S. Food, Drug, and Cosmetic Act (FDCA) and the regulations promulgated under that Act, the FDA regulates the design, development, clinical trials, testing, manufacture, packaging, labeling, storage, distribution and promotio
» More Articles for MASI

Headlines

Articles On GuruFocus.com
Inova Fair Oaks Hospital Casts Masimo Patient SafetyNet(TM) to Help Improve Patient Outcomes and Red Jan 14 2015 
Masimo Unveils MightySat(TM) at Consumer Electronics Show -- First Fingertip Pulse Oximeter With Mas Jan 05 2015 
Masimo to Present at 33rd Annual J.P. Morgan Healthcare Conference Dec 30 2014 
Masimo Announces Global Launch of Multigas Monitoring for the Root(R) Patient Monitoring and Connect Dec 16 2014 
Masimo Receives 2014 Zenith Award at the American Association of Respiratory Care Congress Dec 10 2014 
Masimo iSpO2(TM) Pulse Oximeter Featured in Fitness Book by Tour de France Champion Greg LeMond Dec 04 2014 
Masimo Announces FDA 510(k) Clearance of Radius-7(TM) -- First rainbow(R) SET(R) Noninvasive Wearabl Dec 01 2014 
New Clinical Study Shows Accuracy of Masimo Noninvasive Spot-Check Hemoglobin (SpHb(R)) in Trauma Pa Nov 05 2014 
Arkansas Heart Hospital Upgrades to Masimo SET(R) Pulse Oximetry, Resulting in Significant Reduction Oct 23 2014 
Masimo to Report Third Quarter 2014 Financial Results After Market Close on Wednesday, October 29th Oct 17 2014 

More From Other Websites
Masimo Hits 52-Week High on Favorable Q1 & Court Verdict - Analyst Blog May 20 2015
Court upholds Masimo's victory in patent suit against Philips units May 19 2015
Court Upholds Award of $467 Million to Masimo for Philips' Patent Infringement May 19 2015
Court Upholds Award of $467 Million to Masimo for Philips' Patent Infringement May 19 2015
MASIMO CORP Financials May 15 2015
Perioperative Enhanced Recovery Program That Included Masimo PVI Led to Significant Reductions in... May 14 2015
Un programme de rétablissement optimisé périopératoire qui comprenait le PVI de Masimo a... May 14 2015
Perioperative Enhanced Recovery Program That Included Masimo PVI Led to Significant Reductions in... May 14 2015
MASIMO CORP Files SEC form 8-K, Other Events May 12 2015
10-Q for Masimo Corp. May 08 2015
Masimo (MASI) Q1 Earnings, Revenues Beat; View Raised - Analyst Blog May 07 2015
Masimo beats Street 1Q forecasts May 06 2015
Masimo beats Street 1Q forecasts May 06 2015
Masimo Reports First Quarter 2015 Financial Results May 06 2015
Masimo Corp Earnings Call scheduled for 4:30 pm ET today May 06 2015
MASIMO CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 06 2015
Masimo Reports First Quarter 2015 Financial Results May 06 2015
Q1 2015 Masimo Corp Earnings Release - After Market Close May 06 2015
L'oxymètre de pouls MightySat de Masimo assure le monitorage d'athlètes de haut niveau à... Apr 29 2015
Masimo's MightySat Pulse Oximeter Monitoring Elite Athletes at Vertical Blue Freediving Competition Apr 29 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK